AAS
DMAC icon

Avantax Advisory Services’s DiaMedica Therapeutics DMAC Stock Holding History

Avantax Advisory Services’s Portfolio DMAC Stock Details DMAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-12,500
Closed -$35.5K – 1670
2023
Q4 		$35.5K Buy
+12,500
New +$30.9K ﹤0.01% 1550

Other funds holding DMAC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CLG
Cooperman Leon G $3.05B AUM 42.78% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
PAPAIJV
Paragon Associates & Paragon Associates II Joint Venture Dallas, Texas $73.6M AUM 61.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
AC
Aristides Capital Louisville, Kentucky $462M AUM 28.94% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Avantax Advisory Services's DMAC Position: Q1 2024 in Review

Avantax Advisory Services sold out of DiaMedica Therapeutics (DMAC) in Q1 2024, closing a stake of 12,500 shares — an estimated $35.5K sold.

Avantax Advisory Services first reported a position in DMAC in Q4 2023 and held it in 1 quarter. The position peaked at $35.5K in Q4 2023. 32 funds tracked by Wall St. Rank hold DMAC as of Q1 2024.

  • Avantax Advisory Services reported no remaining DiaMedica Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Avantax Advisory Services sold 12,500 DiaMedica Therapeutics shares in Q1 2024, an estimated $35.5K.
  • Avantax Advisory Services first reported a position in DiaMedica Therapeutics in Q4 2023 and held it in 1 quarter.
  • Avantax Advisory Services's DiaMedica Therapeutics position peaked at $35.5K in Q4 2023.
  • 32 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q1 2024.

Based on Avantax Advisory Services's 13F filing for Q1 2024, filed 8 May 2024.